Stay updated with breaking news from Valtech Cardio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Venus Medtech ( Hangzhou ) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its acquisition of Cardiovalve Ltd. (Cardiovalve),
HANGZHOU, China, Dec. 8, 2021 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus MedTech, 2500.HK), a leading, innovative Chinese structural heart disease treatment company, announced its
Venus Medtech will pay $150 million immediately and a further $150 million dependent on reaching regulatory milestones.
The global incidence of valvular heart defects in the ageing geriatric population will give an upswing to the demand for annuloplasty procedures for tricuspid valve repair. According to WHO, 2.0% of global deaths from cardiovascular diseases are related to rheumatic heart disease. Innovations in minimally invasive p...
The global incidence of valvular heart defects in the ageing geriatric population will give an upswing to the demand for annuloplasty procedures for tricuspid valve repair. According to WHO, 2.0% of global deaths from cardiovascular diseases are related to rheumatic heart disease. Innovations in minimally invasive p...